Table 1. Demographic data of included subjects.

Patient characteristics	Controls (n = 30)	Stable MCI (n = 52)	MCI-AD (n = 47)	MCI-other (n = 20)
Age at baseline (years)	72±8	64±9a	74±6b	72±9b
Gender (Male/Female)	13/17	28/24	11/3b	13/7
APOE ε4 carrier (%)	23	48	81a , b	30
MMSE at baseline (0–30 p)	29.3±1.0	27.3±1.8a	26.7±1.4a	27.0±1.6a
Annual decrease in MMSE score	−0.01±0.33	−0.21±0.45	3.3±2.5a , b	2.6±2.3a , b
CSF Tau, pg/ml	283±97	335±203	792±367a , b	497±609
CSF P-tau, pg/ml	57±13	63±16	96±29a , b	61±31
CSF Aβ42, pg/ml	733±161	555±191a	317±98a , b	571±179a

Data are the mean (± standard deviation) or number (%).Only P-values<0.01 are considered significant, because of correction for multiple comparisons (all groups were compared to both controls and stable MCI).

^a P<0.01 vs Controls.

^b P<0.01 vs Stable MCI.

Abbreviations: Stable MCI, patients with MCI with stable cognitive functions during a follow-up period of 5.2 years; MCI-AD, patients with MCI who developed Alzheimer's disease during follow-up; MCI-other, patients with MCI who developed other types of dementia during follow-up; CSF, cerebrospinal fluid; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination.